Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma

Table 1 Characteristics of all the patients

Patients	Age	Sex	BCLC stage	HK	Tumor site(s)	Radiotherapy target	Dose of radiotherapy	Cycle(s) of PPV-DC-CTL
P1	66	Male	B	IIIB	Liver	Partial liver mass	PGTV 5 Gy*10f; PTV 2.5 Gy*10f	3
P2	56	Female	B	IIIB	Liver	Partial liver mass	PGTV 5 Gy*10f; PTV 2.5 Gy*10f	3
P3	54	Male	C	IVa	Liver and portal vein tumor thrombosis	Portal vein tumor thrombosis	PGTV 5 Gy*10f; PTV 2.5 Gy*10f	2
P4	37	Male	C	IVa	Bone and lung	Bone metastasis	PGTV 4 Gy*10f; PTV 3 Gy*10f	3
P5	56	Male	C	IVa	Liver and peritoneal metastases	Peritoneal metastasis	PTV 0.5 Gy BID *2f	2
P6	45	Male	B	IIIB	Liver	-	-	2
P7	43	Male	B	IIIB	Liver	Partial liver mass	PGTV 5 Gy*10f; PTV 2.5 Gy*10f	3
P8	59	Male	C	IVa	Liver and lung	Partial lung mass	PGTV 5 Gy*10f; PTV 2.5 Gy*10f	1
P9	72	Male	C	IVa	Lung	-	-	2